Reuters -- AstraZeneca has pulled regulatory submissions for its experimental drug Zactima plus chemotherapy as a treatment for lung cancer, dealing a blow to its new product pipeline and hitting its shares.
Reuters -- AstraZeneca has pulled regulatory submissions for its experimental drug Zactima plus chemotherapy as a treatment for lung cancer, dealing a blow to its new product pipeline and hitting its shares.
